(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 October 2013 (10.10.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/151762 A1

(51) International Patent Classification:
*C07K 16/18* (2006.01)

(21) International Application Number:
PCT/US2013/032341

(22) International Filing Date:
15 March 2013 (15.03.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/620,880 5 April 2012 (05.04.2012) US

(71) Applicants: **AC IMMUNE S.A.** [CH/CH]; PSE Building B-EPFL, CH-1015 Lausanne (CH). **KATHOLIEKE UNIVERSITEIT LEUVEN** [BE/BE]; KU Leuven Research & Development, Waaistraat 6 - Box 5105, B-3000 Leuven (BE). **GENENTECH, INC.** [US/US]; 1 DNA Way, South San Francisco, California 94080 (US).

(72) Inventors: **PFEIFER, Andrea**; Route De Fenil 16A, CH-1806 St-Legier (CH). **MUHS, Andreas**; Chemin Des Alouettes 12, CH-1053 Cugy (CH). **PIHLGREN, Maria**; Chemin Du Tessin 6B, CH-1052 Mont-sur-Lausanne (CH). **ADOLFSSON, Oskar**; Chemin De Larry 16, CH-1038 Bercher (CH). **LEUVEN, Fred, Van**; Hertogenlaan 18, B-3210 Linden (BE). **AYALON, Gai**; 1295 Rimer Drive, Moraga, CA 94556 (US). **DI CARA, Danielle, Marie**; 2211 Castro Street, Unit 204, San Francisco, CA 94131 (US). **HOTZEL, Isidro**; 432 Swallowtall Court, Brisbane, CA 94005 (US).

(74) Agents: **CORUZZI, Laura, A.** et al.; Jones Day, 222 East 41st Street, New York, NY 10017-6702 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published**:

— *with international search report (Art. 21(3))*

*[Continued on next page]*

(54) Title: HUMANIZED TAU ANTIBODY





Figure 1

(57) Abstract: The present invention provides, methods end composites for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular,, the Invention relates to humanized antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers to rnethods and compositions involving antibodies for the therapeutic and diagnostic use In the treatment of tauopathies including Alzheimer's Disease (AD).

WO 2013/151762 A1

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*